This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Colorectal cancer	Epiregulin (EREG)	<i>In vitro</i> and mouse studies suggest inhibiting EREG could help treat colitis-associated colorectal cancer. EREG expression was upregulated in tumor tissues from patients and mice with colitis-associated colorectal cancer but not in tissues from those with spontaneous colorectal cancer. In a mouse model for colitis-associated cancer, <i>Ereg</i> knockout decreased tumor growth compared with no knockout. Next steps could include developing pharmacological inhibitors of EREG.	Patent and licensing status unavailable	Neufert, C. <i>et al. J. Clin. Invest.</i> ; published online March 15, 2013; doi:10.1172/JCI63748 Contact: Clemens Neufert, University of Erlangen-Nuremberg, Erlangen, Germany e-mail: clemens.neufert@uk-erlangen.de
SciBX 6(12); doi:10.1038/scibx.2013.285 Published online March 28, 2013				